Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

Kamdar was recruited from Stanford in 2015 to start the lymphoma programme at CU Anschutz. Her goal was to focus on aggressive lymphomas by creating more effective, less toxic treatments that ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

These chronic diseases contrast with the aggressive non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma, which can be fatal within weeks or months of diagnosis if not treated. Diffuse ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

These treatments show particular promise for Hodgkin lymphoma patients with limited options. For patients with aggressive lymphoma or those experiencing relapse, stem cell transplantation provides ...

which is possible in follicular lymphoma, though unlikely in more aggressive lymphomas." In a situation where the patient has low tumor burden, but is symptomatic, the approved treatment is ...

For slow-growing lymphomas, long-term survival is common, although they cannot be cured. More aggressive tumors are more dangerous, but a permanent cure is possible. The lymphoma type, its effects ...

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.